Home West Coast San Diego, CA Tr1X COMPANY
Clinical Phase 2
6 open jobs · last seen Oct 23, 2026 · 5 sources
Tr1X develops cell therapies using proprietary genetic reprogramming and closed-system production processes. From company website Source · Oct 12, 2026
Keywords: cell therapy Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis (MS) Primary Progressive Multiple Sclerosis (MS) Secondary Progressive Crohns Disease Hematologic Malignancy GvHD GVHD,Acute Chronic GVHD Hematopoietic Stem Cell Transplant Adult B-Cell Acute Lymphoblastic Leukemia Adult T-Cell Acute Lymphoblastic Leukemia Acute Myeloid Leukemia in Remission Myelodysplastic Syndromes Cancer Remission TRX103 TRX319 Show all 19 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Director, Clinical Operations San Diego, CA Oct 22, 2026 Oct 23, 2026 Director, Medical & Regulatory Writing San Diego, CA Oct 11, 2026 Oct 12, 2026 Director / Senior Director, Program Management San Diego, CA Oct 6, 2026 Oct 9, 2026 Senior Scientist, Immunology - Targeted LNP Delivery San Diego, CA Sep 8, 2026 Oct 9, 2026 Principal Scientist, LNP Platform & Process Development San Diego, CA Aug 28, 2026 Oct 9, 2026
See all 6 jobs
At a glance HQ San Diego, CA source Region West Coast Stage Clinical Phase 2 Latest trial Phase 1/Phase 2: Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis (Mar 1, 2026) source Timeline Oct 9, 2026 Board tracked Radar started tracking this company’s job board (6 open jobs at last check). source ↗ Mar 1, 2026 Trial start Phase 1/Phase 2: Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis source ↗ May 5, 2025 Trial start Phase 1/Phase 2: Treatment of Moderate to Severe Refractory Crohn's Disease source ↗ Apr 4, 2025 Grant Government grant: $8M (total, as published), announced Apr 4, 2025. Source: company's own press page. source ↗ Apr 8, 2024 Trial start Phase 1: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) source ↗ Upcoming milestones 2028-08 (ESTIMATED) · Phase 1/Phase 2 · Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis · NCT07477639 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 6 Title Location (from posting, not HQ) Employer posted First seen Level Director, Clinical Operations San Diego, CA Oct 22, 2026 Oct 23, 2026 Not stated Director, Medical & Regulatory Writing San Diego, CA Oct 11, 2026 Oct 12, 2026 Senior Description Director / Senior Director, Program Management San Diego, CA Oct 6, 2026 Oct 9, 2026 Senior Description Senior Scientist, Immunology - Targeted LNP Delivery San Diego, CA Sep 8, 2026 Oct 9, 2026 Senior Description Principal Scientist, LNP Platform & Process Development San Diego, CA Aug 28, 2026 Oct 9, 2026 Senior Description Senior Director, Quality San Diego, CA Jul 27, 2026 Oct 9, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Funding Last 2 years.
Apr 4, 2025 Government grant: $8M (total, as published), announced Apr 4, 2025. Source: company's own press page. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT07477639 Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis Phase 1/Phase 2 Recruiting Mar 1, 2026 2028-08 (estimated) NCT06721962 Treatment of Moderate to Severe Refractory Crohn's Disease Phase 1/Phase 2 Recruiting May 5, 2025 Jan 30, 2026 (estimated) NCT06462365 Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1 Recruiting Apr 8, 2024 Apr 15, 2026 (estimated)
